The Impact of Age at Diagnosis and Tumor Location on Overall Survival Rates in Colon Cancer
DOI:
https://doi.org/10.62382/jcbt.v2i4.84Keywords:
Colorectal cancer, Age of diagnosis, Site of tumor, Overall survival, Colon adenocarcinomaAbstract
Objectives: Colorectal cancer (CRC) is one of the most common cancers worldwide, with different survival rates. In this study, we aimed to investigate the impact of age at diagnosis and tumor site among treated and untreated subjects diagnosed with CRC on overall survival rates.
Methods: Data were obtained from open data sources (cBioPortal). Comprising 364 anonymized samples diagnosed with CRC (colon adenocarcinoma), we included patients with available data for the age of diagnosis, treatment regimen, site of tumor, and overall survival. The survival analysis was performed using the Kaplan-Meier method, and the difference in survival was analyzed with a log-rank test.
Results: A total of 364 anonymized samples diagnosed with colorectal cancer (CRC, specifically colon adenocarcinoma) were included in the analysis. The results showed no significant dominance of sex in the study population. According to the site of the tumor, the most common sites for colon cancer were in the sigmoid and rectosigmoid colon, representing 36% of the cases, with a survival rate of 67% and 86% for treated and untreated groups, respectively. The least sites were hepatic flexure & splenic flexure at 12.6% with survival rates of 78% and 86% for treated and untreated groups, respectively. In addition, results showed a better survival rate in the older age group (67-100), representing 54.4% of the cases, with a survival rate of 75% and 80% for treated and untreated groups, respectively. The other age group (0-66), representing 45.6% of cases, had lower survival rates of 60% and 85% for treated and untreated groups, respectively.
Conclusion: The current study showed that right-sided colorectal cancer is more aggressive with lower survival rates compared to left-sided colorectal cancer, and the age of diagnosis in CRC is proportionally related to survival rates. The site of the tumor and age of diagnosis might be important factors in the survival rates of the CRC, which can be supported by other research on different population groups.
Downloads
References
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: A Cancer Journal for Clinicians. 2024, 74(1), 12-49. DOI: 10.3322/caac.21820
Muñoz RA, Miranda FJ, Ramírez AA, Regalado D, Ortiz JC, Gallardo G, et al. Differences in risk factors, demographic and clinicopathologic characteristics at diagnosis between proximal and distal colon cancer: A multicenter retrospective cohort analysis. Revista de Gastroenterología de México. 2025, 90(3), 373-380. DOI: 10.1016/j.rgmxen.2025.09.001
Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Przegla̜d Gastroenterologiczny. 2019, 14(2), 89-103. DOI: 10.5114/pg.2018.81072
Okamoto M, Shiratori Y, Yamaji Y, Kato J, Ikenoue T, Togo G, et al. Relationship between age and site of colorectal cancer based on colonoscopy findings. Gastrointestinal Endoscopy. 2002, 55(4), 548-551. DOI: 10.1067/mge.2002.122335
Iida Y, Kawai K, Tsuno NH, Ishihara S, Yamaguchi H, Sunami E, et al. Proximal shift of colorectal cancer along with aging. Clinical Colorectal Cancer. 2014, 13(4), 213-218. DOI: 10.1016/j.clcc.2014.06.005
Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is there a difference in survival between right- versus left-sided colon cancers? Annals of Surgical Oncology. 2008, 15(9), 2388-2394. DOI: 10.1245/s10434-008-0015-y
Renzi C, Lyratzopoulos G, Hamilton W, Maringe C, Rachet B. Contrasting effects of comorbidities on emergency colon cancer diagnosis: a longitudinal data-linkage study in England. BMC Health Services Research. 2019, 19(1), 311. DOI: 10.1186/s12913-019-4075-4
Quipourt V, Jooste V, Cottet V, Faivre J, Bouvier AM. Comorbidities alone do not explain the undertreatment of colorectal cancer in older adults: a French population-based study. Journal of the American Geriatrics Society. 2011, 59(4), 694-698. DOI: 10.1111/j.1532-5415.2011.03334.x
Isah Tsamiya R, Mohd Nafi SN, Che Jalil NA, Mat Zin AA. The Clinicopathological Characteristics of Young-Onset Versus Adult-Onset Colorectal Cancer: A Tertiary Hospital-Based Study. The Malaysian Journal of Medical Sciences. 2024, 31(1), 200-211. DOI: 10.21315/mjms2024.31.1.17
Akinkuotu AC, Maduekwe UN, Hayes-Jordan A. Surgical outcomes and survival rates of colon cancer in children and young adults. American Journal of Surgery. 2021, 221(4), 718-724. DOI: 10.1016/j.amjsurg.2021.02.010
Perrott S, Laurie K, Laws K, Johnes A, Miedzybrodzka Z, Samuel L. Young-onset colorectal cancer in the North East of Scotland: survival, clinico-pathological features and genetics. BMC Cancer. 2020, 20(1), 108. DOI: 10.1186/s12885-020-6606-0
van Eeghen EE, Bakker SD, van Bochove A, Loffeld RJ. Impact of age and comorbidity on survival in colorectal cancer. Journal of Gastrointestinal Oncology. 2015, 6(6), 605. DOI: 10.3978/j.issn.2078-6891.2015.070
Onyoh EF, Hsu WF, Chang LC, Lee YC, Wu MS, Chiu HM. The Rise of Colorectal Cancer in Asia: Epidemiology, Screening, and Management. Current Gastroenterology Reports. 2019, 21(8), 36. DOI: 10.1007/s11894-019-0703-8
Ismail I, Chan HK, Aiman SS, Muhammad Radzi AH. A 10-year registry-based incidence, mortality, and survival analysis of colorectal cancer in Northern Malaysia. Journal of Cancer Research and Therapeutics. 2022, 18(4), 931-938. DOI: 10.4103/jcrt.JCRT_544_20
Wan Ibrahim NR, Chan HK, Soelar SA, Azmi AN, Mohd Said R, Abu Hassan MR. Incidence, Clinico-demographic Profiles and Survival Rates of Colorectal Cancer in Northern Malaysia: Comparing Patients Above and Below 50 Years of Age. Asian Pacific Journal of Cancer Prevention. 2020, 21(4), 1057-1061. DOI: 10.31557/APJCP.2020.21.4.1057
Hussan H, Patel A, Le Roux M, Cruz-Monserrate Z, Porter K, Clinton SK, et al. Rising Incidence of Colorectal Cancer in Young Adults Corresponds With Increasing Surgical Resections in Obese Patients. Clinical and Translational Gastroenterology. 2020, 11(4), e00160. DOI: 10.14309/ctg.0000000000000160
Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nature Reviews. Gastroenterology & Hepatology. 2019, 16(12), 713-732. DOI: 10.1038/s41575-019-0189-8
Duan BJ, Zhao YN, Bai J, Wang JH, Duan XL, Luo XH, et al. Colorectal cancer: an overview. Exon Publications. 2022, 1-12.
Granados-Romero JJ, Valderrama-Treviño AI, Contreras-Flores EH, Barrera-Mera B, Herrera Enríquez M, Uriarte-Ruíz K, et al. Colorectal cancer: a review. International Journal of Research in Medical Sciences. 2017, 5(11), 4667. DOI: 10.18203/2320-6012.ijrms20174914
Nakagawa-Senda H, Hori M, Matsuda T, Ito H. Prognostic impact of tumor location in colon cancer: the Monitoring of Cancer Incidence in Japan (MCIJ) project. BMC Cancer. 2019, 19(1), 431. DOI: 10.1186/s12885-019-5644-y
Brouwer NPM, van der Kruijssen DEW, Hugen N, de Hingh IHJT, Nagtegaal ID, Verhoeven RHA, et al. The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival. Annals of Surgical Oncology. 2020, 27(5), 1580-1588. DOI: 10.1245/s10434-019-08100-5
Price TJ, Beeke C, Ullah S, Padbury R, Maddern G, Roder D, et al. Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease? Cancer. 2015, 121(6), 830-835. DOI: 10.1002/cncr.29129
Zheng C, Jiang F, Lin H, Li S. Clinical characteristics and prognosis of different primary tumor location in colorectal cancer: a population-based cohort study. Clinical & Translational Oncology. 2019, 21(11), 1524-1531. DOI: 10.1007/s12094-019-02083-1
Alese OB, Zakka K, Huo X, Jiang R, Shaib WL, Akce M, et al. Perioperative therapy in metastatic colorectal cancer: Pattern of use and survival outcomes. Journal of Surgical Oncology. 2021, 123(2), 596-605. DOI: 10.1002/jso.26278
Loupakis F, Yang DY, Yau L, Feng SB, Cremolini C, Zhang W, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. Journal of the National Cancer Institute. 2015, 107(3), dju427. DOI: 10.1093/jnci/dju427
Blakely AM, Lafaro KJ, Eng OS, Ituarte PHG, Fakih M, Lee B, et al. The Association of Tumor Laterality and Survival After Cytoreduction for Colorectal Carcinomatosis. The Journal of Surgical Research. 2020, 248, 20-27. DOI: 10.1016/j.jss.2019.10.001
Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, et al. Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis. JAMA Oncology. 2017, 3(2), 211-219. DOI: 10.1001/jamaoncol.2016.4227
Odeny TA, Farha N, Hildebrandand H, Allen J, Vazquez W, Martinez M, et al. Association between Primary Perioperative CEA Ratio, Tumor Site, and Overall Survival in Patients with Colorectal Cancer. Journal of Clinical Medicine. 2020, 9(12), 3848. DOI: 10.3390/jcm9123848
Snyder M, Bottiglieri S, Almhanna K. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer. Reviews on Recent Clinical Trials. 2018, 13(2), 139-149. DOI: 10.2174/1574887113666180328104109
Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. European Journal of Cancer. 2017, 70, 87-98. DOI: 10.1016/j.ejca.2016.10.007
Mizukami T, Takahashi M, Sunakawa Y, Yuki S, Kagawa Y, Takashima A, et al. Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy. Targeted Oncology. 2022, 17(3), 343-353. DOI: 10.1007/s11523-022-00880-3
Li DD, Fu Q, Li M, Li J, Yin C, Zhao J, et al. Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: a meta-analysis. Future Oncology. 2017, 13(12), 1115-1127. DOI: 10.2217/fon-2016-0468
Jiang YL, Zhao MY, Tang WX, Zheng XP. Impacts of systemic treatments on health-related quality of life for patients with metastatic colorectal cancer: a systematic review and network meta-analysis. BMC Cancer. 2024, 24(1), 188. DOI: 10.1186/s12885-024-11937-z
Brezden-Masley C, Polenz C. Current practices and challenges of adjuvant chemotherapy in patients with colorectal cancer. Surgical Oncology Clinics of North America. 2014, 23(1), 49-58. DOI: 10.1016/j.soc.2013.09.009
Sabharwal A, Kerr D. Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future. Expert Review of Anticancer Therapy. 2007, 7(4), 477-487. DOI: 10.1586/14737140.7.4.477
Hotta T, Takifuji K, Arii K, Yokoyama S, Matsuda K, Higashiguchi T, et al. Clinical impact of adjuvant chemotherapy on patients with stage III colorectal cancer: l-LV/5FU chemotherapy as a modified RPMI regimen is an independent prognostic factor for survival. Anticancer Research. 2006, 26(2B), 1425-1432. PMID: 16619554
Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll HJ, et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clinical Colorectal Cancer. 2015, 14(1), 1-10. DOI: 10.1016/j.clcc.2014.11.002
Goyle S, Maraveyas A. Chemotherapy for colorectal cancer. Digestive Surgery. 2005, 22(6), 401-414. DOI: 10.1159/000091441
Morris VK, Kennedy EB, Baxter NN, Benson AB 3rd, Cercek A, Cho M, et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. Journal of Clinical Oncology. 2023, 41(3), 678-700. DOI: 10.1200/JCO.22.01690
Smith HG, Nilsson PJ, Shogan BD, Harji D, Gambacorta MA, Romano A, et al. Neoadjuvant treatment of colorectal cancer: comprehensive review. BJS Open. 2024, 8(3), zrae038. DOI: 10.1093/bjsopen/zrae038
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Mazhar Salim Al Zoubi, Nadeen Abdelrazzaq Alwraikat, Qusai Nabeel Swedan, Sara Radi Al-Atoom, Marah Ali Al-Jarrah, Zayneb Rasheed Al-Jarrah, Ayeh Khaled Obeidat, Neemat Nedal Albdour, Almu’atasim Khamees, Sema Misir, Riyadh Muhaidat, Raed M. Al-Zoubi
This work is licensed under a Creative Commons Attribution 4.0 International License.
